Results of a study examining the cost effectiveness of lenalidomide combined with rituximab for treatment of relapsed indolent lymphomas.
Home / Resource Library / Lenalidomide plus rituximab Vs rituximab alone in relapsed or refractory indolent lymphoma: A cost-effectiveness analysis